Cyprotex Share Discussion Threads

[rrb] 13/6/2016 09:13

This purchase of the flow cytometry machine for biologics is actually a very smart move given immuno-oncology is one of hottest areas of medical research at the moment....

Yes, agreed with Husbod - no takeover but a 'technical' reason that triggered a strategic review.

CLN issue will continue to keep share price around this level....unless CLN holders negotiate a mutually beneficial restructuring.

[p1nkfish] 11/6/2016 09:53

woody, if they clear the notes early won't they have to pay the interest lost to holders that were intending to hold to the end?

Harwood looking to move on SBS might be a harbinger for action here too.

[battlebus2] 10/6/2016 10:18

Continuing upwards, with the AGM in a few days we may have some clarity on the position...

[bahiflyer] 10/6/2016 10:04

Me too Salty. Looking really solid ahead of next weeks AGM and perhaps a further trading plus strategic review update.
Interesting bit of news yesterday regarding the Bio equipment buy which I almost missed amongst all the Singer noise, especially in light of Harwood bidding for SBS.
Would love to know what their plans are.

[saltaire111] 08/6/2016 21:47

I love this company. salty

[husbod] 07/6/2016 15:31

Undoubtedly due to the recent polls showing Brexit ahead.

Actually, unless there's a big buy in the background the current volume doesn't suggest much at all. Best guess is either we've been tipped or peeps think an RNS is about to be released on the outcome of the review.

We are tightly held so small volumes can affect the share price disproportionately (either way).

[saltaire111] 07/6/2016 15:04

That's some move today! Anyone any idea what's happening?

Salty

[battlebus2] 07/6/2016 12:36

Welcome Woody, moving well today, some news imminent??

[husbod] 07/6/2016 11:38

Not aware of any take-over woody - they are just looking at all restructuring options with the loan notes being one of the main issues I suspect.

Anyway nothing much happening at the moment and I trust this process doesn't mean that management are distracted from the main matter of running the business effectively.

[woodcutter] 07/6/2016 09:36

bb2 well done for starting new thread thx

I've still retained my PIK convertible loan notes since selling my holding some way back. Anyone know what's going to happen with these in the event of the take over proceeding?

I'm assuming we'll receive the diffrence between 60p (the convertible loan note price) and the final agreed offer price.

woody

[p1nkfish] 17/5/2016 08:39

And it's addressing repeated doses and more than one route for the dose.
Very impressive.
CRX is a desirable property.

[battlebus2] 17/5/2016 07:38

New enhanced version of ChemPK announced this morning.

[p1nkfish] 11/5/2016 12:22

The debt is down to the convertible loan notes convertible at 60p.

As the share price rises the debt burden increases as the cost of the convertibles increases too. They pay 5% on the notes until redemption.

The current Strategic Review is intended to help square this circle for all concerned.

[dazzaa] 11/5/2016 09:17

I'm new to CRX and would like to invest, doing a bit of research there looks like a lot of debt with the company, can any long term follower give some info to form a rational decision.

[p1nkfish] 10/5/2016 20:41

Thank you for the new thread.

Is indeed a sweet British success at the cross-roads of bio. Very ethical too and a positive contributor to the human condition. Baxter and team deserve every penny.

The wording was deliberate so even the Board are behind the growth curve.

[husbod] 10/5/2016 16:39

yep, thanks battlebus.

Not a bad day for us LTHs.

Old buywell must be chomping at the bit. Anyone know how long does a ban last if indeed that is the reason for his disappearance?

[lancasterbomber] 10/5/2016 15:56

Well done for starting new thread

[battlebus2] 10/5/2016 15:32

Trading Update

Cyprotex PLC, the preclinical ADME-Tox services company, provides an update on revenue and profit guidance for the first quarter of 2016.

The financial performance of the Company for the first quarter of the year is significantly ahead of the Boards' expectations, comparative period performance and internal budgets.

The Board also confirms that the Company's strategic review is progressing.

[battlebus2] 10/5/2016 15:31

I started a new thread where we can see charts etc

[battlebus2] 10/5/2016 15:27

CHARTS
!

[chadders] 10/5/2016 10:25

Added a few more this morning following the update (trade not showing though). To me the words will have been chosen carefully and it says more than meets the eye. Hoping for significant upside from here.

[husbod] 10/5/2016 09:57

Yep bahiflyer I wondered whether the reference to the "boards" expectations rather than the "markets" expectations was significant or just a bit of imprecise terminology. Hopefully it was entirely intentional.

This bb isn't the same without buywell, like him or loathe him and the number of posters suggests this share is well below the radar. We need more publicity as a genuine British success story at the forefront of a very important scientific/medical market.

Still looking at the strategic review - hope it doesn't involve a demerger or something of the American operation and is just looking at the financing/loan notes.

[bahiflyer] 10/5/2016 07:57

Nice update, 'significantly ahead of the boards expectations' never mind the market's.
Even better.
Also underpins the statement yesterday, must be generating cash hand over fist so not too worried about the note derivatives even if it acts as an anchor..for now.

[p1nkfish] 10/5/2016 07:53

yes, looking at current market cap it should be towards 2x+ without streching credulity much at all.

[rrb] 10/5/2016 07:43

the loan note will stop share price from rocketing. That said, someone made a good point about the tax rebate from the note, which offsets a decent chunk of the interest. We are looking at >£20m in revenues by next year. Given the operational gearing, this thing should be trading at multiples of current market price.